YOLFTbeta
Inventiva S.A

Inventiva S.A

IVA · PA · Healthcare / Biotechnology

3.39EUR-0.19 (-5.44%)

Price History

Full chart

Market Stats

Previous Close3.59
Open3.55
Day Range3.31 – 3.56
52-Week Range2.73 – 6.20
Volume408.93K
Market Cap742.91M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.53
Dividend Yield0.00%
Beta0.92
50-Day Avg3.72
200-Day Avg4.31

About

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Andrew Obenshain
  • Employees87
  • Headquarters50 rue de Dijon, Daix, France, 21121, France
  • Websitehttps://inventivapharma.com

Leadership

  • Mr. Andrew ObenshainChief Executive Officer · b. 1974
  • Dr. Pierre Broqua Ph.D.Co-Founder · b. 1962
  • Mr. Jean VolatierExecutive VP Finance & Corporate Social Responsibility · b. 1965
  • Dr. Martine Zimmermann Pharm.D.Executive VP of Regulatory Affairs & Quality Assurance and Head of Regulatory Affairs · b. 1969
  • Mr. Jason A. Campagna M.D., Ph.D.President of Research & Development and Chief Medical Officer · b. 1966
  • Mr. Axel-Sven MalkomesChief Financial Officer · b. 1967
  • Mr. Christopher Benecchi M.B.A.Chief Operating Officer · b. 1972
  • Ms. Susan ColesChief Legal Officer · b. 1966
  • Ms. Pamela HerbsterChief People Officer
  • Ms. Pascaline Clerc Ph.D.Executive Vice President of External & Corporate Affairs · b. 1980

Financials

Income Statement

Currency: EUR2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue3.06M3.28M4.87M9.45M6.52M3.20M7.00M372.00K4.19M12.18M17.48M14.72M4.48M
Growth (%)-+7.13%+48.49%+93.77%-30.96%-50.97%+118.89%-94.68%+1027.42%+190.39%+43.50%-15.75%-69.55%
Cost of Revenue1.68M1.52M1.40M1.49M1.24M967.00K-846.00K1.02M995.00K-23.00K5.53M2.91M
Gross Profit1.38M1.76M3.47M7.96M5.28M2.23M7.00M372.00K3.18M12.18M17.50M9.20M1.57M
Gross Margin45.11%53.59%71.18%84.27%81.05%69.75%100.00%100.00%75.75%100.00%100.13%62.47%35.07%
Operating Expense13.85M15.23M18.98M20.98M26.20M35.48M37.31M30.09M55.29M69.29M120.21M106.76M137.90M
Operating Income-12.47M-13.47M-15.51M-13.02M-20.92M-33.25M-30.31M-29.72M-52.11M-57.11M-102.71M-97.56M-136.33M
Operating Margin-406.81%-410.22%-318.17%-137.83%-320.76%-1040.13%-433.15%-7988.71%-1242.58%-468.92%-587.68%-662.58%-3040.98%
EBITDA-11.42M-12.43M-13.91M-11.14M-22.00M-32.04M-28.76M-27.83M-52.27M-55.41M-102.04M-96.69M-133.42M
EBITDA Margin-372.51%-378.48%-285.28%-117.98%-337.37%-1002.22%-410.95%-7481.18%-1246.33%-454.98%-583.86%-656.72%-2976.04%
Net Income-7.13M-7.49M-8.82M-7.05M-17.23M-33.62M-30.22M-31.62M-49.64M-54.27M-110.43M-184.21M-354.14M
Net Income Margin-232.82%-228.26%-181.00%-74.59%-264.22%-1051.49%-431.85%-8500.81%-1183.50%-445.64%-631.84%-1251.10%-7899.58%
R&D13.75M16.28M19.64M22.14M26.73M31.64M33.79M23.72M48.45M60.47M110.01M90.88M87.04M
R&D as % of Total Revenue448.59%496.01%402.89%234.44%409.96%989.58%482.87%6375.54%1155.27%496.50%629.47%617.22%1941.62%
Interest Expense6302.94K6.06K7.55K5.32K206.00K19.00K66.00K142.00K707.00K5.22M12.18M33.56M
Interest Expense % of Total Revenue0.02%0.09%0.12%0.08%0.08%6.44%0.27%17.74%3.39%5.81%29.89%82.71%748.70%

Balance Sheet

Currency: EUR2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets87.12M73.13M60.58M48.86M74.37M79.81M56.96M138.92M121.98M116.00M69.56M118.97M249.51M
Total Liabilities28.11M21.63M17.81M13.14M10.36M18.22M15.57M27.71M33.12M70.53M101.59M225.61M278.03M
Total Equity59.01M51.51M42.77M35.72M64.01M61.60M41.39M111.21M88.87M45.48M-32.03M-106.65M-28.52M
Cash13.52M17.14M22.60M24.87M59.05M56.69M35.84M105.69M86.55M86.74M26.92M96.56M99.31M
Total Debt160.39K104.46K698.00K627.60K482.07K2.20M114.00K10.06M10.12M34.51M37.49M54.33M59.86M
Net Debt-13.36M-17.03M-21.90M-24.24M-58.57M-54.49M-35.73M-92.43M-76.43M-52.22M10.57M-42.23M-39.45M

Cash Flow

Currency: EUR2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-16.01M-14.79M-13.98M-14.86M-17.00M-34.21M-28.40M-30.59M-47.63M-44.93M-81.61M-85.93M-104.88M
Investing Cash Flow18.37M18.46M18.85M17.20M6.17M-420.00K-826.00K-8.56M-1.79M8.87M-7.73M8.74M-133.19M
Financing Cash Flow240.49K-60.49K591.84K-70.86K45.01M32.27M8.38M111.67M25.45M37.27M29.08M145.59M241.29M
Capital Expenditure1.92M1.29M968.99K227.94K428.03K549.00K136.00K292.00K534.00K561.00K540.00K333.00K247.00K
Free Cash Flow-17.93M-16.08M-14.95M-15.09M-17.43M-34.76M-28.54M-30.88M-48.16M-45.49M-82.15M-86.26M-105.13M
Dividends Paid---0------000
FCF to OCF111.99%108.73%106.93%101.53%102.52%101.60%100.48%100.95%101.12%101.25%100.66%100.39%100.24%
Dividend Paid to FCF---0.00%------0.00%0.00%0.00%

Earnings

Report DateSep 26, 2017May 15, 2018Sep 27, 2018May 15, 2019Sep 25, 2019Nov 13, 2019Mar 10, 2020May 14, 2020Jul 6, 2020Nov 12, 2020Mar 4, 2021May 13, 2021Jul 28, 2021Nov 10, 2021Mar 7, 2022May 17, 2022Jul 7, 2022Nov 10, 2022Mar 29, 2023May 16, 2023Sep 28, 2023Nov 21, 2023Mar 27, 2024May 21, 2024Sep 25, 2024Nov 21, 2024Mar 26, 2025Apr 15, 2025Sep 29, 2025Nov 21, 2025Apr 1, 2026Sep 25, 2026Apr 1, 2027
EPS Estimate0.000.000.00-0.780.000.000.00-0.23-0.70-0.32-0.68-0.27-0.68-0.29-0.730.00-0.000.07-0.21-0.73-0.45-0.59-0.43-0.72-0.50-0.41-0.41-0.54-0.25-0.30--
EPS Actual-0.60-0.51-0.86-0.78-0.930.00-0.39-0.23-0.30-0.32-0.390.00-0.600.00-0.670.00-0.720.000.07-0.27-1.31-0.49-0.59-0.44-0.81-0.73-1.68-2.00-1.38-0.260.00--
Surprise---0.00%---0.00%57.14%0.00%42.65%100.00%11.76%100.00%8.22%---4.71%-27.83%-79.45%-7.64%-0.07%-3.56%-12.21%-46.50%-310.66%-388.88%-154.28%-1.27%100.00%--
TimingAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hours-After-hours-------After-hoursAfter-hours

Key Statistics & Ratios

Market Cap742.91M
Enterprise Value537.69M
Trailing P/E0.00
Forward P/E0.00
Price / Sales302.49
Price / Book2.00
EPS-0.53
Book Value-0.148
Revenue (TTM)2.46M
Gross Profit (TTM)1.92M
EBITDA-149.06M
Profit Margin0.00%
Operating Margin-5337.32%
Return on Equity-989.05%
Return on Assets-42.69%
Shares Outstanding236.22M
Shares Float165.57M
Beta0.92
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%